ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Nutrition and Supplements
Effect of alpha glycerylphosphorylcholine (Alpha-GPC) on memory and other health issues
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 134563" data-attributes="member: 3"><p>Has anyone used α-Glycerophosphocholine (GPC) ? It gives me focus. I use <a href="https://www.amazon.com/Alpha-Choline-Supplement-Pharmaceutical-Capsules/dp/B00XWQSD7G/ref=sr_1_1_sspa?ie=UTF8&qid=1530221375&sr=8-1-spons&keywords=alpha+-+gpc&psc=1" target="_blank">this product</a></p><p></p><p>Here is a study that also shows increased GH and liver fat oxidation.</p><p></p><p></p><p><strong>Glycerophosphocholine enhances growth hormone secretion and fat oxidation in young adults</strong></p><p></p><p>by Kawamura, Takashi, M.S.|Okubo, Takeshi, Ph.D.|Sato, Koji, Ph.D.|Fujita, Satoshi, Ph.D.|Goto, Kazushige, Ph.D.|Hamaoka, Takafumi, M.D., Ph.D.|Iemitsu, Motoyuki, Ph.D</p><p>Nutrition, 2012, Volume 28, Issue 11</p><p></p><p>Abstract</p><p></p><p>Objective α-Glycerophosphocholine (GPC) is a putative acetylcholine precursor that potentially increases growth hormone secretion through the action of acetylcholine-stimulated catecholamine. The aim of this study was to investigate acute physiologic responses to a single intake of GPC.</p><p></p><p>Methods Eight healthy male subjects (25 ± 1 y old) ingested GPC 1000 mg or a placebo in a double-blind randomized crossover study. Fasting blood samples were obtained before the administration of GPC (baseline) and 60 and 120 min after administration. All subjects repeated the identical protocol using the placebo.</p><p></p><p>Results Plasma free choline levels significantly increased at 60 and 120 min after GPC administration. Plasma growth hormone secretion was increased significantly 60 min after taking GPC, whereas no significant change was observed with the placebo. In addition, the serum free fatty acid was increased 120 min after GPC ingestion, but no changes were seen with the placebo. Moreover, serum acetoacetate and 3-hydroxybutyrate levels, which are indices of hepatic fat oxidation, were increased at 120 min after taking GPC, whereas the placebo had no effect.</p><p></p><p>Conclusion These findings suggest that a single dose of GPC increases growth hormone secretion and hepatic fat oxidation, with concomitant increases in choline levels, in young adults.</p><p></p><p>__________</p><p></p><p>Here is another study measuring strength:</p><p></p><p><strong>The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength</strong></p><p></p><p>David BellarEmail authorView ORCID ID profile, Nina R. LeBlanc and Brian Campbell</p><p></p><p>Journal of the International Society of Sports Nutrition201512:42</p><p></p><p>Ergogenic aides are widely used by fitness enthusiasts and athletes to increase performance. Alpha glycerylphosphorylcholine (A-GPC) has demonstrated some initial promise in changing explosive performance. The purpose of the present investigation was to determine if 6 days of supplementation with A-GPC would augment isometric force production compared to a placebo. Thirteen college-aged males (Means ± SD; Age: 21.9 ± 2.2 years, Height: 180.3 ± 7.7 cm, Weight: 87.6 ± 15.6 kg; VO2 max: 40.08 ± 7.23 ml O2*Kg(-1)*min(-1), Body Fat: 17.5 ± 4.6%) gave written informed consent to participate in the study. The study was a double blind, placebo controlled, cross-over design. The participants reported to the lab for an initial visit where they were familiarized with the isometric mid thigh pull in a custom squat cage on a force platform and upper body isometric test against a high frequency load cell, and baseline measurements were taken for both. The participant then consumed either 600 mg per day of A-GPC or placebo and at the end of 6 days performed isometric mid thigh pulls and an upper body isometric test. A one-week washout period was used before the participants' baseline was re-measured and crossed over to the other treatment. The A-GPC treatment resulted in significantly greater isometric mid thigh pull peak force change from baseline (t = 1.76, p = 0.044) compared with placebo (A-GPC: 98.8. ± 236.9 N vs Placebo: -39.0 ± 170.9 N). For the upper body test the A-GPC treatment trended towards greater change from baseline force production (A-GPC: 50.9 ± 67.2 N Placebo: -14.9 ± 114.9 N) but failed to obtain statistical significance (t = 1.16, p = 0.127). A-GPC is effective at increasing lower body force production after 6 days of supplementation. Sport performance coaches can consider adding A-GPC to the diet of speed and power athletes to enhance muscle.</p><p></p><p>____________________</p><p></p><p>Here is another study looking at cognitive function.</p><p></p><p><strong>Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, double-blind, randomized...</strong></p><p></p><p>by De Jesus Moreno Moreno, Maria</p><p>Clinical Therapeutics, 2003, Volume 25, Issue 1</p><p></p><p>Background: Parallel with the development of hypotheses regarding cholinergic involvement in geriatric memory dysfunction, the first attempts to treat patients with Alzheimer's disease (AD) involved the cholinergic-precursor loading approach. Despite encouraging early results, well-controlled clinical trials did not confirm a clinical utility of cholinergic precursors such as choline and lecithin (phosphatidylcholine) in AD. Objective: This study assessed the efficacy and tolerability of the cholinergic precursor choline alfoscerate (CA) in the treatment of cognitive impairment due to mild to moderate AD. Methods: In this multicenter, double-blind, randomized, placebo-controlled trial, patients affected by mild to moderate dementia of the Alzheimer type were treated with CA (400-mg capsules) or placebo capsules, 3 times daily, for 180 days. Efficacy outcome measures that were assessed at the beginning of the investigation and after 90 and 180 days of treatment included scores of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), the Mini-Mental State Examination (TM) (MMSE), the Global Deterioration Scale (GDS), the Alzheimer's Disease Assessment Scale-Behavioral Subscale (ADAS-Behav), all items of the Alzheimer's Disease Assessment Scale (ADAS-Total), and the Clinical Global Impression (CGI) scale. The Global Improvement Scale (GIS) score was assessed after 90 and 180 days of treatment.</p><p></p><p>Results: A total of 261 patients (132 in the CA group, 129 in the placebo</p><p>group) were enrolled in the study. The mean (SD) age in the CA group was 72.2</p><p>(7.5) years (range, 60-80 years), and in the placebo group it was 71.7 (7.4) years</p><p>(range, 60-80 years). The CA group comprised 105 women and 27 men; the</p><p>placebo group, 94 women and 35 men. The mean decrease in ADAS-Cog score</p><p>in patients treated with CA was 2.42 points after 90 days of treatment and 3.20</p><p>points at the end of the study (day 180) (P < 0.001 vs baseline for both), whereas</p><p>in patients receiving placebo the mean increase in ADAS-Cog score was 0.36</p><p>point <1 after 90 days of treatment and 2.90 points after 180 days of treatment</p><p>(P < 0.001 vs baseline). In the CA group, all other assessed parameters (MMSE,</p><p>GDS, ADAS-Behav, ADAS-Total, and CGI) consistently improved after 90 and 180</p><p>days versus baseline, whereas in the placebo group they remained unchanged or</p><p>worsened. Statistically significant differences were observed between treatments</p><p>after 90 and 180 days in ADAS-Cog, MMSE, GDS, ADAS-Total, and CGI scores</p><p>and after 180 days of treatment in ADAS-Behav and GIS scores.</p><p></p><p>Conclusion: The results of this study suggest the clinical usefulness and tolerability</p><p>of CA in the treatment of the cognitive symptoms of dementia disorders of the</p><p>Alzheimer type. (Clin Ther. 2003;25:178-193)</p><p></p><p><a href="https://www.excelmale.com/forum/threads/has-anyone-used-alpha-gpc.11958/" target="_blank">Has Anyone Used Alpha-GPC ?</a></p><p></p><p><a href="https://selfhacked.com/blog/top-18-scientific-health-benefits-choline-cdp-choline-alpha-gpc/#Pros" target="_blank">Top 17 Scientific Health Benefits of Choline (CDP-Choline, Alpha-GPC) - Selfhacked</a></p><p></p><p></p><p><a href="https://jissn.biomedcentral.com/articles/10.1186/s12970-017-0196-5" target="_blank">Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 134563, member: 3"] Has anyone used α-Glycerophosphocholine (GPC) ? It gives me focus. I use [URL='https://www.amazon.com/Alpha-Choline-Supplement-Pharmaceutical-Capsules/dp/B00XWQSD7G/ref=sr_1_1_sspa?ie=UTF8&qid=1530221375&sr=8-1-spons&keywords=alpha+-+gpc&psc=1']this product[/URL] Here is a study that also shows increased GH and liver fat oxidation. [B]Glycerophosphocholine enhances growth hormone secretion and fat oxidation in young adults[/B] by Kawamura, Takashi, M.S.|Okubo, Takeshi, Ph.D.|Sato, Koji, Ph.D.|Fujita, Satoshi, Ph.D.|Goto, Kazushige, Ph.D.|Hamaoka, Takafumi, M.D., Ph.D.|Iemitsu, Motoyuki, Ph.D Nutrition, 2012, Volume 28, Issue 11 Abstract Objective α-Glycerophosphocholine (GPC) is a putative acetylcholine precursor that potentially increases growth hormone secretion through the action of acetylcholine-stimulated catecholamine. The aim of this study was to investigate acute physiologic responses to a single intake of GPC. Methods Eight healthy male subjects (25 ± 1 y old) ingested GPC 1000 mg or a placebo in a double-blind randomized crossover study. Fasting blood samples were obtained before the administration of GPC (baseline) and 60 and 120 min after administration. All subjects repeated the identical protocol using the placebo. Results Plasma free choline levels significantly increased at 60 and 120 min after GPC administration. Plasma growth hormone secretion was increased significantly 60 min after taking GPC, whereas no significant change was observed with the placebo. In addition, the serum free fatty acid was increased 120 min after GPC ingestion, but no changes were seen with the placebo. Moreover, serum acetoacetate and 3-hydroxybutyrate levels, which are indices of hepatic fat oxidation, were increased at 120 min after taking GPC, whereas the placebo had no effect. Conclusion These findings suggest that a single dose of GPC increases growth hormone secretion and hepatic fat oxidation, with concomitant increases in choline levels, in young adults. __________ Here is another study measuring strength: [B]The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength[/B] David BellarEmail authorView ORCID ID profile, Nina R. LeBlanc and Brian Campbell Journal of the International Society of Sports Nutrition201512:42 Ergogenic aides are widely used by fitness enthusiasts and athletes to increase performance. Alpha glycerylphosphorylcholine (A-GPC) has demonstrated some initial promise in changing explosive performance. The purpose of the present investigation was to determine if 6 days of supplementation with A-GPC would augment isometric force production compared to a placebo. Thirteen college-aged males (Means ± SD; Age: 21.9 ± 2.2 years, Height: 180.3 ± 7.7 cm, Weight: 87.6 ± 15.6 kg; VO2 max: 40.08 ± 7.23 ml O2*Kg(-1)*min(-1), Body Fat: 17.5 ± 4.6%) gave written informed consent to participate in the study. The study was a double blind, placebo controlled, cross-over design. The participants reported to the lab for an initial visit where they were familiarized with the isometric mid thigh pull in a custom squat cage on a force platform and upper body isometric test against a high frequency load cell, and baseline measurements were taken for both. The participant then consumed either 600 mg per day of A-GPC or placebo and at the end of 6 days performed isometric mid thigh pulls and an upper body isometric test. A one-week washout period was used before the participants' baseline was re-measured and crossed over to the other treatment. The A-GPC treatment resulted in significantly greater isometric mid thigh pull peak force change from baseline (t = 1.76, p = 0.044) compared with placebo (A-GPC: 98.8. ± 236.9 N vs Placebo: -39.0 ± 170.9 N). For the upper body test the A-GPC treatment trended towards greater change from baseline force production (A-GPC: 50.9 ± 67.2 N Placebo: -14.9 ± 114.9 N) but failed to obtain statistical significance (t = 1.16, p = 0.127). A-GPC is effective at increasing lower body force production after 6 days of supplementation. Sport performance coaches can consider adding A-GPC to the diet of speed and power athletes to enhance muscle. ____________________ Here is another study looking at cognitive function. [B]Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, double-blind, randomized...[/B] by De Jesus Moreno Moreno, Maria Clinical Therapeutics, 2003, Volume 25, Issue 1 Background: Parallel with the development of hypotheses regarding cholinergic involvement in geriatric memory dysfunction, the first attempts to treat patients with Alzheimer's disease (AD) involved the cholinergic-precursor loading approach. Despite encouraging early results, well-controlled clinical trials did not confirm a clinical utility of cholinergic precursors such as choline and lecithin (phosphatidylcholine) in AD. Objective: This study assessed the efficacy and tolerability of the cholinergic precursor choline alfoscerate (CA) in the treatment of cognitive impairment due to mild to moderate AD. Methods: In this multicenter, double-blind, randomized, placebo-controlled trial, patients affected by mild to moderate dementia of the Alzheimer type were treated with CA (400-mg capsules) or placebo capsules, 3 times daily, for 180 days. Efficacy outcome measures that were assessed at the beginning of the investigation and after 90 and 180 days of treatment included scores of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), the Mini-Mental State Examination (TM) (MMSE), the Global Deterioration Scale (GDS), the Alzheimer's Disease Assessment Scale-Behavioral Subscale (ADAS-Behav), all items of the Alzheimer's Disease Assessment Scale (ADAS-Total), and the Clinical Global Impression (CGI) scale. The Global Improvement Scale (GIS) score was assessed after 90 and 180 days of treatment. Results: A total of 261 patients (132 in the CA group, 129 in the placebo group) were enrolled in the study. The mean (SD) age in the CA group was 72.2 (7.5) years (range, 60-80 years), and in the placebo group it was 71.7 (7.4) years (range, 60-80 years). The CA group comprised 105 women and 27 men; the placebo group, 94 women and 35 men. The mean decrease in ADAS-Cog score in patients treated with CA was 2.42 points after 90 days of treatment and 3.20 points at the end of the study (day 180) (P < 0.001 vs baseline for both), whereas in patients receiving placebo the mean increase in ADAS-Cog score was 0.36 point <1 after 90 days of treatment and 2.90 points after 180 days of treatment (P < 0.001 vs baseline). In the CA group, all other assessed parameters (MMSE, GDS, ADAS-Behav, ADAS-Total, and CGI) consistently improved after 90 and 180 days versus baseline, whereas in the placebo group they remained unchanged or worsened. Statistically significant differences were observed between treatments after 90 and 180 days in ADAS-Cog, MMSE, GDS, ADAS-Total, and CGI scores and after 180 days of treatment in ADAS-Behav and GIS scores. Conclusion: The results of this study suggest the clinical usefulness and tolerability of CA in the treatment of the cognitive symptoms of dementia disorders of the Alzheimer type. (Clin Ther. 2003;25:178-193) [URL='https://www.excelmale.com/forum/threads/has-anyone-used-alpha-gpc.11958/']Has Anyone Used Alpha-GPC ?[/URL] [URL='https://selfhacked.com/blog/top-18-scientific-health-benefits-choline-cdp-choline-alpha-gpc/#Pros']Top 17 Scientific Health Benefits of Choline (CDP-Choline, Alpha-GPC) - Selfhacked[/URL] [URL='https://jissn.biomedcentral.com/articles/10.1186/s12970-017-0196-5']Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Nutrition and Supplements
Effect of alpha glycerylphosphorylcholine (Alpha-GPC) on memory and other health issues
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top